Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial

Trials

Humberto Silos³  Angélica Ruiz-Franco³  Gerónimo Aguayo-Leytte⁴  Maria Raquel Huerta-Franco¹  Erick de la Cruz-Estrada²  José Luis Ruiz-Sandoval⁵  Antonio Arauz³  Juan Manuel Marquez-Romero³ 

[1] Department of Applied Sciences to Work, Health Science Division, University of Guanajuato, 37320 Leon, Guanajuato, Mexico;Hospital De Alta Especialidad “Dr. Juan Graham Casasus”. Carretera a la Isla SN. Col. Miguel Hidalgo, Villahermosa, Tabasco, Mexico;Stroke Clinic, Instituto Nacional de Neurología y Neurocirugía “MVS”, Av. Insurgentes Sur # 3877, Col. La Fama, Mexico City, 14269, Mexico;Centenario Hospital “Miguel Hidalgo”, Galeana Sur 465. Col. Obraje, Aguascalientes, Mexico;Hospital Civil de Guadalajara “Fray Antonio Alcalde”. Hospital 278, Col. El Retiro, Torre de Especialidades, 8vo. piso, Universidad de Guadalajara Guadalajara, Jalisco, 44280, Mexico

关键词: Randomized controlled trial;    Fluoxetine;    Motor recovery;    Stroke;    Intracerebral hemorrhage;   

Others  :  1094517
DOI  :  10.1186/1745-6215-14-77

 received in 2012-12-29, accepted in 2013-03-01,  发布年份 2013

【 摘 要 】

Background

Spontaneous, nontraumatic intracerebral hemorrhage (ICH) is a subtype of stroke that causes a great amount of disability and economic and social burden. This is particularly true in developing countries where it accounts for between 20% and 50% of all strokes. Pharmacological and surgical interventions have been attempted to reduce the mortality and disability caused by ICH, with unsuccessful results. Recently, the use of fluoxetine in addition to physical rehabilitation has been proven useful to improve motor recovery following cerebral infarct. The purpose of this study is to test whether a 3-month treatment with fluoxetine enhances motor recovery in nondepressed patients with acute intracerebral hemorrhage.

Methods/design

Our study is a randomized, double-blind, placebo-controlled, multicenter clinical trial. We will recruit 86 patients with intracerebral hemorrhage of both sexes, aged >18 years, from four Mexican hospitals. The patients will receive either 20 mg of fluoxetine or a placebo once daily for 90 days. The primary outcome is the mean change in the Fugl-Meyer Motor Scale score between inclusion (day 0) and day 90. The secondary outcomes will be changes in the Barthel Index, the Modified Rankin scale and the National Institutes of Health stroke scale. The outcomes will be measured at day 42 ± 7days and at day 90, for a total of four visits with each subject (at screening and at 0, 42 and 90 days).

Discussion

Current guidelines recommend early supported hospital discharge and home-based rehabilitation programs as the only cost-effective intervention to aid the recovery of patients with intracerebral hemorrhage. Nevertheless, such interventions are dependent on available resources and funding, which make them very difficult to implement in developing countries. We believe that the identification of a helpful pharmacological intervention to aid the motor recovery of these patients will constitute a breakthrough that will have a major impact in reducing the burden of disease caused by this subtype of stroke worldwide, especially in the developing world.

Trial registration

Current Controlled Trials NCT01737541

【 授权许可】

   
2013 Marquez-Romero et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Morgenstern LB, Hemphill JC 3rd, Anderson C, Becker K, Broderick JP, Connolly ES Jr, Greenberg SM, Huang JN, MacDonald RL, Messe SR, Mitchell PH, Selim M, Tamargo RJ, American Heart Association Stroke Council and Council on Cardiovascular Nursing: Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association . Stroke 2010, 41:2108-2129.
• [2]Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF: Spontaneous intracerebral hemorrhage. N Engl J Med 2001, 344:1450-1460.
• [3]Saposnik G, Del Brutto OH: Stroke in South America: a systematic review of incidence, prevalence, and stroke subtypes. Stroke 2003, 34:2103-2107.
• [4]Zahuranec DB, Brown DL, Lisabeth LD, Gonzales NR, Longwell PJ, Eden SV, Smith MA, Garcia NM, Morgenstern LB: Differences in intracerebral hemorrhage between Mexican Americans and non-Hispanic whites. Neurology 2006, 66:30-34.
• [5]Romano JG, Arauz A, Koch S, Dong C, Marquez JM, Artigas C, Merlos M, Hernandez B, Roa LF, Rundek T, Sacco RL: Disparities in Stroke Type and Vascular Risk Factors Between 2 Hispanic Populations in Miami and Mexico City. J Stroke Cerebrovasc Dis 2012. Epub ahead of print
• [6]Steiner T, Petersson J, Al-Shahi Salman R, Christensen H, Cordonnier C, Csiba L, Harnof S, Krieger D, Mendelow D, Molina C, Montaner J, Overgaard K, Roine RO, Schmutzhard E, Tatlisumak T, Toni D, Stapf C, European Research Network on Intracerebral Haemorrhage: European research priorities for intracerebral haemorrhage . Cerebrovasc Dis 2011, 32:409-419.
• [7]Staykov D, Huttner HB, Kohrmann M, Bardutzky J, Schellinger PD: Novel approaches to the treatment of intracerebral haemorrhage. Int J Stroke 2010, 5:457-465.
• [8]Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, Freo U, Piron L, Battistin L: Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 1996, 27:1211-1214.
• [9]Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, Rascol O, Chollet F: Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 2001, 50:718-729.
• [10]Zittel S, Weiller C, Liepert J: Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair 2008, 22:311-314.
• [11]Acler M, Robol E, Fiaschi A, Manganotti P: A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. J Neurol 2009, 256:1152-1158.
• [12]Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, Bejot Y, Deltour S, Jaillard A, Niclot P, Guillon B, Moulin T, Marque P, Pariente J, Arnaud C, Loubinoux I: Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial . Lancet Neurol 2011, 10:123-130.
• [13]Mikami K, Jorge RE, Adams HP Jr, Davis PH, Leira EC, Jang M, Robinson RG: Effect of antidepressants on the course of disability following stroke. Am J Geriatr Psychiatr 2011, 19:1007-1015.
• [14]Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S: The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance. Scand J Rehabil Med 1975, 7:13-31.
• [15]Mahoney FI, Barthel DW: Functional Evaluation: The Barthel Index. Md State Med J 1965, 14:61-65.
• [16]Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370.
• [17]López-Roig S, Terol MC, Pastor-Mira MA, Neipp MC, Massutí B, Rodríguez-Marín J: Anxiety and Depression. The HAD scale validation in cancer patients. Revista de Psicología de la Salud 2000, 12:127-155.
• [18]Aben I, Verhey F, Lousberg R, Lodder J, Honig A: Validity of the beck depression inventory, hospital anxiety and depression scale, SCL-90, and hamilton depression rating scale as screening instruments for depression in stroke patients. Psychosomatics 2002, 43:386-393.
• [19]Kelly PJ, Furie KL, Shafqat S, Rallis N, Chang Y, Stein J: Functional recovery following rehabilitation after hemorrhagic and ischemic stroke. Arch Phys Med Rehabil 2003, 84:968-972.
• [20]Schepers VP, Ketelaar M, Visser-Meily AJ, de Groot V, Twisk JW, Lindeman E: Functional recovery differs between ischaemic and haemorrhagic stroke patients. J Rehabil Med 2008, 40:487-489.
• [21]Katrak PH, Black D, Peeva V: Do stroke patients with intracerebral hemorrhage have a better functional outcome than patients with cerebral infarction? PM R 2009, 1:427-433.
• [22]Nannetti L, Paci M, Pasquini J, Lombardi B, Taiti PG: Motor and functional recovery in patients with post-stroke depression. Disabil Rehabil 2005, 27:170-175.
• [23]Rost NS, Smith EE, Chang Y, Snider RW, Chanderraj R, Schwab K, FitzMaurice E, Wendell L, Goldstein JN, Greenberg SM, Rosand J: Prediction of functional outcome in patients with primary intracerebral hemorrhage: the FUNC score. Stroke 2008, 39:2304-2309.
• [24]Jang SH, Kim SH, Cho SH, Choi BY, Cho YW: Demonstration of motor recovery process in a patient with intracerebral hemorrhage. NeuroRehabilitation 2007, 22:141-145.
• [25]Ward NS, Newton JM, Swayne OB, Lee L, Thompson AJ, Greenwood RJ, Rothwell JC, Frackowiak RS: Motor system activation after subcortical stroke depends on corticospinal system integrity. Brain 2006, 129:809-819.
• [26]Cho SH, Kim SH, Choi BY, Kang JH, Lee CH, Byun WM, Jang SH: Motor outcome according to diffusion tensor tractography findings in the early stage of intracerebral hemorrhage. Neurosci Lett 2007, 421:142-146.
• [27]Sharma N, Cohen LG: Recovery of motor function after stroke. Dev Psychobiol 2012, 54:254-262.
• [28]Gonzenbach RR, Taegtmeyer AB, Luft A, Russmann S: Fluoxetine and motor recovery after ischaemic stroke. Lancet Neurol 2011, 10:499-500. author reply 500-501
• [29]Ruiz-Sandoval JL, Chiquete E, Garate-Carrillo A, Ochoa-Guzman A, Arauz A, Leon-Jimenez C, Carrillo-Loza K, Murillo-Bonilla LM, Villarreal-Careaga J, Barinagarrementeria F, Cantu-Brito C: Spontaneous intracerebral hemorrhage in Mexico: results from a Multicenter Nationwide Hospital-based Registry on Cerebrovascular Disease (RENAMEVASC). Rev Neurol 2011, 53:705-712.
• [30]Ferri CP, Schoenborn C, Kalra L, Acosta D, Guerra M, Huang Y, Jacob KS, Llibre Rodriguez JJ, Salas A, Sosa AL, Williams JD, Liu Z, Moriyama T, Valhuerdi A, Prince MJ: Prevalence of stroke and related burden among older people living in Latin America, India and China . J Neurol Neurosurg Psychiatry 2011, 82:1074-1082.